Keyword: Sun Pharmaceutical
Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.
Sun Pharma will bring distribution of its formulations in India in house after a partnership featured in a controversy that took a toll on its share prices.
A Sun distributor allegedly inked transactions worth $816 million with a firm controlled by Sun’s co-promoter Sudhir Valia.
Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.
Sun Pharma is recalling four lots of the muscle relaxant vecuronium bromide after glass fragments were found.
India scrutinizes whistleblower case against Sun; FDA slaps warning letter on valsartan API maker; Eisai and UCL push anti-tau drug into the clinic.
India’s stock regulators say they're examining a whistleblower complaint against top domestic drugmaker Sun Pharma.
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.